Stocks to sell

It has been a rough past couple of years for Tilray Brands (NASDAQ:TLRY), but more recently, things have started to look up for TLRY stock. Last month, shares in the Canada-based cannabis company began to rally again, on the heels of a well-received quarterly earnings release. Last week, shares spiked in price yet again, except

Investors seeking defensive exposure in this market may turn their attention to mining socks. These companies, involved in locating, extracting, and processing valuable minerals vital for global industries, play an essential role as a growth engine for the global economy. Without various important base metals, entire industries wouldn’t be possible. Indeed, these companies may be

Meme stocks have had an eventful summer, with many popular shares seeing sharp rallies. While enthusiasm may not be back to peak 2021 levels, interest is certainly up. Not all meme stocks are set to prosper, though. In fact, many of the worst meme stocks out there continue to have poor fundamentals and even cloudy

I’m no more certain than the next speculator regarding the fate of bank stocks in 2023. We’re all aware that this year has been a tough one for the sector. The bank runs a few months back were a scary sight to behold. Thankfully, the banking sector has held up, and things are normal again. However, August

This article is an excerpt from the InvestorPlace Digest newsletter. To get news like this delivered straight to your inbox, click here. 2023 has been an incredible year for the stock market. The Nasdaq Composite has risen 34% so far, its best showing since 1983. The macro picture is looking bright, with inflation on the retreat

Investors who’ve dipped their toe into the waters of biotech stocks know that the chances of these stocks crashing and burning is certainly higher than with most sectors. Failure is incredibly common for firms that engage in the development of pharmaceuticals. High costs and long product development timelines combine to produce spectacular failures rates, pretty

By no means is this discussion about meme stocks to sell an indication that you should avoid the sector altogether. Sometimes, it’s good to just have fun (responsibly, of course) in the market. Ultimately, you never know if that wild contrarian wager might turn into something substantive. That, of course, is the main temptation of

With pharmaceutical companies, it’s all about the pipeline of new medications. Drugmakers, and their pharma stocks, are judged based on sales of current medications and potential sales of future prescriptions. Analysts and investors alike are always on the lookout for the next blockbuster drug. This helps to explain why the stocks of pharmaceutical companies with

For a hot minute, Wall Street loved electric vehicle (EV) battery technology company QuantumScape (NYSE:QS). Then, financial traders turned against the company and QS stock quickly coughed up its gains. Frankly, it’s just too risky to invest in QuantumScape now. Don’t get the wrong idea. The investing community is fickle, and any stock is susceptible

It’s the height of summer vacation season, and the stock market is taking a breather after its major rally earlier in the year. For active traders, much of the excitement has moved to penny stocks, with many low-priced equities making huge moves in recent weeks. Investors should avoid the urge to go plunging too aggressively

Payment processing specialist PayPal (NASDAQ:PYPL) is a formerly favored company on Wall Street that’s now in a state of decline. PYPL stock gets a “D” grade because, even if some of PayPal’s financial metrics seem adequate, there are definitely cracks in the foundation. Not long ago, UBS analysts cut their price target on PayPal shares from

As much as I love good dividend stocks, I have very little patience for F-rated dividend stocks that do nothing but drag your portfolio down. As an investor, you deserve better! A great dividend stock can make all the difference in your portfolio. By reinvesting dividends, growth investors can increase their positions and investing power

The U.S. equity valuations continue their remarkable trend upward, well beyond anyone’s expectations in 2023. The major indices appreciated amid expectations of a soft landing for the economy as the Federal Reserve battles inflation. While inflation still sits above the Federal Reserve’s target, it is well below where it was 12 months ago. However, despite

Chimerix (NASDAQ:CMRX), like most clinical-stage biotech stocks, is without question a high-risk play. Yet in contrast to other biotechs, where high potential rewards can outweigh this high risk, that is not necessarily the case here with CMRX stock. Sure, on paper, Chimerix’s future prospects appear very promising. Last year, the company sold a treatment that

Electric vehicles (EVs) are all across the globe and EV adoption is on the rise. With government incentives and price cuts, we will see mass EV adoption in the next five years. EV makers are making the most of this opportunity and ramping up production to meet the rising demand. However, not all EV makers

Some of the top companies on the market just posted poor second-quarter financial results. While company executives always do their best to put a positive spin on their quarterly numbers. there’s no covering up a truly awful print. That includes these seven stocks to avoid after Q2 earnings. Stocks to Avoid After Q2 Earnings: Roblox (RBLX) Source: Michael

Although speculative enterprises tend to draw in a loyal band of followers, certain circumstances call for decisive action, as these small-cap stocks to avoid in August confirms. Nobody wants to be the guy or gal throwing in the towel. However, you can’t ignore clear signs of trouble. Certainly, just because warning signs pop up doesn’t mean

The U.S. housing market has remained surprisingly resilient coming out of the Covid-19 pandemic. The economic recession that has been predicted for more than a year now has not arrived, keeping buyers on the hunt for new homes. And while higher interest rates have led many homeowners to sit tight and put off listing their

Investing in growth stocks can be risky, especially for those migrating into new markets or turnaround ventures. Personally, I’ve experienced losses from such endeavors. Amid rising interest rates, caution is advised for overpriced growth stocks. Despite recent declines, their valuations remain risky. Two factors contribute to their potential downfall: further interest rate hikes and underwhelming

With hopes for lower interest rates and normalizing economic conditions, real estate investment trusts (REITs) have been moving higher. However, as macro uncertainties mount, there are now plenty of REITs to avoid in August. After all, REITs are highly sensitive to interest rates (rising when rates fall, sinking when rates rise). Plus, if it turns